Immuno-oncology has transformed cancer treatment over the past decade, but the field is now entering a more complex and demanding chapter. Checkpoint inhibitors have changed outcomes for many patients, yet primary and acquired resistance remain major challenges. Cellular therapies have revolutionized parts of hematologic oncology, but their broader application in solid tumors remains one of the field’s most urgent scientific questions.

At the same time, personalized cancer vaccines, tumor antigen discovery, biomarker-driven treatment selection, combination immunotherapy strategies, and immune-related toxicity management are reshaping the way clinicians and researchers approach cancer care.

Immuno 2026 will bring together clinicians, investigators, scientists, healthcare professionals, early-career researchers, and patient advocates to examine these developments and discuss how scientific discovery can be translated into more effective, personalized, and accessible treatments for patients worldwide.

Through expert presentations, disease-specific clinical sessions, panel discussions, rapid-fire research talks, and international perspectives, the congress will connect fundamental cancer immunology with translational research and real-world clinical practice.

The Parker Institute for Cancer Immunotherapy is an active research institute working to accelerate the development of breakthrough immune therapies and move promising scientific discoveries toward meaningful treatments for patients.

Its collaborative model connects researchers, academic institutions, nonprofit organizations, and industry partners to address complex challenges in cancer immunotherapy.

Through this partnership, Immuno 2026 will emphasize scientific collaboration, translational research, clinical innovation, and global dialogue in advancing the future of immuno-oncology.

The congress will also recognize the Parker Institute’s 10-year journey and its role in supporting collaborative research across major frontiers of cancer immunotherapy.

The Immuno 2026 scientific program will focus on the most important scientific, clinical, and global challenges currently shaping immuno-oncology.

The program is being developed around major themes including checkpoint immunotherapy, the tumor microenvironment, cellular therapies, personalized cancer vaccines, biomarker-driven patient selection, toxicity management, disease-specific clinical immunotherapy, global access, and health equity.

Invited faculty will be asked to indicate their preferred scientific sections and presentation interests to help align speakers with the final agenda.

Session chairs and scientific leaders will be identified as the program continues to develop.

Who Should Attend?

Immuno 2026 is designed for professionals and stakeholders involved in cancer research, diagnosis, treatment, supportive care, and patient advocacy, including:

Medical oncologists
Hematologists and hemato-oncologists
Immunologists
Translational researchers
Laboratory scientists
Clinical investigators
Pathologists and molecular diagnosticians
Surgical oncologists
Radiation oncologists
Oncology nurses
Advanced practice providers
Oncology pharmacists
Biotechnology and pharmaceutical researchers
Clinical research professionals
Medical students, residents, and fellows
Patient advocates, patients, and caregivers

Why Attend?

Learn From Global Experts
Hear perspectives from leading clinicians, scientists, researchers, and multidisciplinary specialists working across cancer immunology and immunotherapy.

Explore Emerging Science
Review developments in biomarkers, resistance, cellular therapies, combination treatments, and next-generation immune-based approaches.

Connect Research With Practice
Understand how scientific discoveries and clinical evidence can inform treatment decisions and improve patient care.

Examine Unmet Challenges
Discuss treatment resistance, immune-related toxicities, patient selection, access barriers, and disparities in immunotherapy delivery.

Join an International Scientific Exchange
Connect with participants representing different specialties, institutions, countries, and healthcare systems.

Partnership & Collaboration Opportunities
Shushan Hovsepyan
Senior Vice President, OncoDaily
Email: shushan.hovsepyan@oncodaily.com
Phone: +1 571 775 9710

Event-Related Inquiries
Inessa Mkhitaryan
Head of Global Events, OncoDaily
Email: inessa.mkhitaryan@oncodaily.com

General Inquiries
Email: info@oncodaily.com